{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:01:23Z","timestamp":1780678883907,"version":"3.54.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3400501"],"award-info":[{"award-number":["2022YFC3400501"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3400504"],"award-info":[{"award-number":["2022YFC3400504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425104"],"award-info":[{"award-number":["82425104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82150208"],"award-info":[{"award-number":["82150208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bcp.2026.117984","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:00:12Z","timestamp":1776351612000},"page":"117984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Discovery of novel CSF1R inhibitor for triple-negative breast cancer (TNBC) treatment through TAMs reprogramming"],"prefix":"10.1016","volume":"250","author":[{"given":"Wenjie","family":"Sha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfeng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bcp.2026.117984_b0005","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191820","article-title":"Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth","volume":"217","author":"Ma","year":"2020","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.bcp.2026.117984_b0010","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.7150\/jca.18457","article-title":"Breast Cancer Cell Line Classification and its Relevance with Breast Tumor Subtyping","volume":"8","author":"Dai","year":"2017","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.117984_b0015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-020-04222-w","article-title":"Tumor microenvironment promotes breast cancer chemoresistance","volume":"87","author":"Mehraj","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117984_b0020","first-page":"61","article-title":"Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative \u201ccold\u201d triple-negative breast cancer","volume":"25","author":"Guo","year":"2023","journal-title":"Bioact. Mater."},{"issue":"9","key":"10.1016\/j.bcp.2026.117984_b0025","doi-asserted-by":"crossref","first-page":"E419","DOI":"10.1016\/S1470-2045(20)30234-5","article-title":"Turning up the heat on non-immunoreactive tumours: opportunities for clinical development","volume":"21","author":"de Olza","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117984_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114298","article-title":"B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy","volume":"183","author":"Cheng","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117984_b0035","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41556-019-0373-7","article-title":"Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms","volume":"21","author":"Kim","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117984_b0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: an accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J. Biomed. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.117984_b0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117984_b0050","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s43018-024-00775-4","article-title":"Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment","volume":"5","author":"Tharp","year":"2024","journal-title":"Nature Cancer."},{"key":"10.1016\/j.bcp.2026.117984_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114354","article-title":"Targeting tumor-associated macrophages as an antitumor strategy","volume":"183","author":"Cheng","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117984_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114990","article-title":"Targeting tumor associated macrophages in hepatocellular carcinoma","volume":"199","author":"Xu","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117984_b0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-024-01559-0","article-title":"Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy","volume":"17","author":"Toledo","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.117984_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.643771","article-title":"Macrophage Biology and Mechanisms of Immune suppression in Breast Cancer","volume":"12","author":"Mehta","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117984_b0075","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ncb3330","article-title":"The ever-expanding role of HIF in tumour and stromal biology","volume":"18","author":"LaGory","year":"2016","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117984_b0080","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-12-195941","article-title":"Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia","volume":"114","author":"Fang","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.117984_b0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","article-title":"The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications","volume":"37","author":"Tamura","year":"2020","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117984_b0090","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13058-024-01831-8","article-title":"CD163+ macrophages in the triple-negative breast tumor microenvironment are associated with improved survival in the Women's Circle of Health Study and the Women's Circle of Health Follow-up Study","volume":"26","author":"Omilian","year":"2024","journal-title":"Breast Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.117984_b0095","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2026.117984_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114884","article-title":"CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment","volume":"245","author":"Wen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117984_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1358750","article-title":"Macrophage colony-stimulating factor and its role in the tumor microenvironment: novel therapeutic avenues and mechanistic insights","volume":"14","author":"Yi","year":"2024","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117984_b0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005610","article-title":"Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages","volume":"10","author":"Zhu","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.117984_b0115","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021857","article-title":"CSF-1 Receptor Signaling in Myeloid Cells","volume":"6","author":"Stanley","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117984_b0120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000182","article-title":"Involvement of the M-CSF\/IL-34\/CSF-1R pathway in malignant pleural mesothelioma","volume":"8","author":"Blondy","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2026.117984_b0125","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s00262-023-03496-2","article-title":"d M, Schlom J; Hamilton D H, Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment","volume":"72","author":"Maldonado","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.bcp.2026.117984_b0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.36401\/JIPO-20-32","article-title":"Clinical Development of Colony-Stimulating factor 1 Receptor (CSF1R) Inhibitors","volume":"4","author":"Lin","year":"2021","journal-title":"Journal of Immunotherapy and Precision Oncology."},{"issue":"16","key":"10.1016\/j.bcp.2026.117984_b0135","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2026.117984_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101514","article-title":"Clinical evaluation of colony-stimulating factor 1 receptor inhibitors","volume":"54","author":"Ordentlich","year":"2021","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117984_b0145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.117984_b0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/17512433.2020.1771179","article-title":"Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors","volume":"13","author":"Baldi","year":"2020","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117984_b0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ctrv.2018.08.010","article-title":"Tumor-associated macrophages in breast cancer: innocent bystander or important player?","volume":"70","author":"Qiu","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.117984_b0160","article-title":"Design, synthesis, andBiological Evaluation ofPotent and selective JAK3Inhibitor for the treatmentof Inflammatory Bowel Disease","author":"Caolin","year":"2025","journal-title":"Journal for Medical Chemistry."},{"key":"10.1016\/j.bcp.2026.117984_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1457323","article-title":"Macrophage variants in laboratory research: most are well done, but some are RAW","volume":"14","author":"Herb","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117984_b0170","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117984_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273044","article-title":"Triple-negative breast cancer influences a mixed M1\/M2 macrophage phenotype associated with tumor aggressiveness","volume":"17","author":"Pe","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcp.2026.117984_b0180","article-title":"Stem cell factor and c-kit are involved in hepatocyte proliferation after partial hepatectomy and acetaminophen-induced liver injury","volume":"132","author":"Hu","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bcp.2026.117984_b0185","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00575.2005","article-title":"Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity","volume":"291","author":"Donahower","year":"2006","journal-title":"American Journal of Physiology-Gastrointestinal and Liver Physiology"},{"issue":"10","key":"10.1016\/j.bcp.2026.117984_b0190","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/s41467-019-11053-8","article-title":"Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations","volume":"1","author":"Rojo","year":"2019","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.117984_b0195","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41467-018-03638-6","article-title":"The role of CSF1R-dependent macrophages in control of the intestinal stem-cell niche","volume":"1","author":"Sehgal","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2026.117984_b0200","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","article-title":"Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer","volume":"40","author":"Kersten","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.117984_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-Associated Macrophages in Tumor Immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117984_b0210","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jmb.2007.01.036","article-title":"The 2.7 \u00c5 crystal structure of the autoinhibited human c-Fms kinase domain","volume":"367","author":"Walter","year":"2007","journal-title":"J. Mol. Biol."},{"issue":"13","key":"10.1016\/j.bcp.2026.117984_b0215","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.3390\/molecules27134194","article-title":"Potential Stereoselective Binding of Trans-(\u00b1)-Kusunokinin and Cis-(\u00b1)-Kusunokinin Isomers to CSF1R","volume":"27","author":"Ayudhya","year":"2022","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.bcp.2026.117984_b0220","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41401-018-0056-0","article-title":"Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R","volume":"39","author":"Liu","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.117984_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110361","article-title":"Inhibition of CSF1R and AKT by (\u00b1)-kusunokinin hinders breast cancer cell proliferation","volume":"129","author":"Rattanaburee","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.bcp.2026.117984_b0230","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.3390\/cancers11121832","article-title":"Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy","volume":"11","author":"Verdeil","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bcp.2026.117984_b0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10928-020-09673-5","article-title":"Disease progression model of 4T1 metastatic breast cancer","volume":"47","author":"Yang","year":"2020","journal-title":"J. Pharmacokinet Pharmacodyn."},{"issue":"1","key":"10.1016\/j.bcp.2026.117984_b0240","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41366-019-0355-7","article-title":"The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice","volume":"44","author":"Merry","year":"2020","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.bcp.2026.117984_b0245","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2021.12.016","article-title":"Hippo\/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ\/IL-34 axis","volume":"527","author":"Wang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.117984_b0250","article-title":"Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117984_b0255","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/cpdd.1240","article-title":"Dosing Recommendation based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in healthy Subjects: Implementation of Model-informed Drug Development Strategy","volume":"12","author":"Zahir","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"8","key":"10.1016\/j.bcp.2026.117984_b0260","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2217\/imt-2018-0156","article-title":"Re-education of macrophages as a therapeutic strategy in cancer","volume":"11","author":"Kowal","year":"2019","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.bcp.2026.117984_b0265","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117984_b0270","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.bcp.2026.117984_b0275","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","article-title":"Cancer-Associated Fibroblasts Neutralize the Anti-tumor effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors","volume":"32","author":"Kumar","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.117984_b0280","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","article-title":"Pathology of triple negative breast cancer","volume":"72","author":"Borri","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117984_b0285","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.117984_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.643771","article-title":"Macrophage Biology and Mechanisms of Immune suppression in Breast Cancer","volume":"12","author":"Mehta","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117984_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.654817","article-title":"Colony Stimulating factor 1 Receptor in Acute Myeloid Leukemia","volume":"11","author":"Sletta","year":"2021","journal-title":"Front. Oncol."},{"issue":"26","key":"10.1016\/j.bcp.2026.117984_b0300","doi-asserted-by":"crossref","first-page":"42076","DOI":"10.18632\/oncotarget.14942","article-title":"Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.bcp.2026.117984_b0305","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/14737140.2020.1757441","article-title":"Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy","volume":"20","author":"Palmerini","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.117984_b0310","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice guidelines: Drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J. Hepatol."},{"issue":"20","key":"10.1016\/j.bcp.2026.117984_b0315","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145296","article-title":"Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment","volume":"131","author":"Su","year":"2021","journal-title":"J. Clin. Investig."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:12:49Z","timestamp":1780675969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226003175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":63,"alternative-id":["S0006295226003175"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117984","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel CSF1R inhibitor for triple-negative breast cancer (TNBC) treatment through TAMs reprogramming","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117984"}}